ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis
Authors:
Open Access
- 1 January 2019
- journal article
- review article
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 57 (1) , 612-624
Abstract
Context: Shenqi FuZheng injection (SFI) has been suggested as a complementary treatment of chemotherapy in China. However, little is known about it in western countries. Objective: This study assesses the clinical effect of SFI combined with chemotherapy for breast cancer patients. Materials and methods: Both English and Chinese databases were searched covering the time period of 1999– 2018 for relevant studies comparing the effect of SFI plus chemotherapy treatment with chemotherapy alone in patients with breast cancer. Target outcomes concerning treatment effect, performance status, immune system and toxic effects were extracted and combined using Stata version 15.0 software. Quality assessment was performed using the Jadad scale. Results: Forty-nine trials were included based on certain selection criteria. Only seven studies were rated as high-quality publications. Results of meta-analysis showed that SFI intervention can significantly improve objective tumour response, performance status, NK, CD3+, CD4+ and CD4+/CD8+ ratio and reduce occurrence of leucopenia, thrombocytopenia, haemoglobin reduction, liver dysfunction, gastrointestinal reaction, nausea and vomiting, bone marrow suppression and ECG changes. However, no significant difference was found between SFI and the control group regarding CD8+ levels, and renal disorders. Discussion and conclusions: SFI intervention appeared to be effective in improving clinical efficacy, immune function and reducing toxicity when combined with chemotherapy for breast cancer. However, our findings still need verification by high-quality trials.Keywords
This publication has 33 references indexed in Scilit:
- Traditional Chinese Medicine in Cancer Care: A Review of Controlled Clinical Studies Published in ChinesePLOS ONE, 2013
- The economic burden of metastatic breast cancer: a U.S. managed care perspectiveBreast Cancer Research and Treatment, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Effects of a Chinese medical herbs complex on cellular immunity and toxicity-related conditions of breast cancer patientsBritish Journal of Nutrition, 2011
- Relations between Phlegm and Generation and Development of Gastric CancerJournal of Traditional Chinese Medicine, 2008
- Clinical Effects of Shenqi Fuzheng Injection in the Neoadjuvant Chemotherapy for Local Advanced Breast Cancer and the Effects on T-lymphocyte SubsetsJournal of Traditional Chinese Medicine, 2008
- Immunoregulatory and Anti-Tumor Effects of Polysaccharopeptide and Astragalus polysaccharides on Tumor-Bearing MiceImmunopharmacology and Immunotoxicology, 2008
- Astragalus saponins induce growth inhibition and apoptosis in human colon cancer cells and tumor xenograftCarcinogenesis, 2006
- Randomized, Controlled Trial of Cyclophosphamide, Methotrexate, and Fluorouracil Versus Cyclophosphamide, Doxorubicin, and Fluorouracil With and Without Tamoxifen for High-Risk, Node-Negative Breast Cancer: Treatment Results of Intergroup Protocol INT-0102Journal of Clinical Oncology, 2005
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996